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Background: Off-label prescribing is common in palliative care. Despite inconsistent reports of the benefit of
nebulised frusemide for breathlessness, its use continues to be reported.
Methods: An online survey was emailed to 249 members of the Australian and New Zealand Society of Palliative
Medicine to estimate the use of nebulised frusemide for breathlessness by Australian physicians involved in
palliative care in the previous 12 months.
Results: There were 52/249 (21%) respondents to the survey. The majority (44/52; 85%) had not prescribed
nebulised frusemide in the previous 12 months. The most common (18/44; 43%) reason for not prescribing
nebulised frusemide was a belief that there was not enough evidence to support its use. Whilst only a few
respondents (8/52; 15%) reported having used nebulised frusemide, all that had used it thought there was at least
some benefit in relieving breathlessness.
Conclusion: This report adds to the series of case studies reporting some benefit from nebulised frusemide in
relieving breathlessnes.
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Off-label prescribing also known as unlabelled or un-
approved prescribing occurs when an approved medica-
tion is used in a way that is not included or disclaimed in
the product information brochure.[1] Off-label use may
occur if the agent is prescribed in a dose, route, indication
or age group for which the agent is not registered with the
appropriate authority. The off-label prescribing of medi-
cines may occur in as many as 20–40% of adults [2,3]. The
extent to which off-label prescribing is based on good clin-
ical data is also concerning. A recent study of over 150
million off-label prescriptions found that 73% had little if
any scientific evidence to support the prescription [2]. Off-
label prescribing is more common in some specialties or
patient population than others [4]. In the relatively new* Correspondence: phillip.newton@uts.edu.au
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reproduction in any medium, provided the orspecialty of palliative care, off-label prescribing occurs
commonly because either the dose or the route of admin-
istration or pharmacological effects were not included in
the original product label [4]. Monitoring these trends is
important in documenting practice trends and the need
for determining future empirical investigations.
Frusemide, a common loop diuretic is primarily used for
the removal of excess fluid and has been approved to be
given as an oral solution, tablet or intravenously. Primarily
used for intractable breathlessness in advanced disease
despite optimal treatment, nebulised frusemide has anec-
dotally been shown to be a useful therapeutic for breath-
lessness [5-7]. Both animal and human studies identified
several possible mechanisms for the action of nebulised
frusemide including enhanced pulmonary receptor activity,
suppression of the pulmonary irritant activity, and vaso-
dilatation although there is no acute haemodynamic effect
[8,9] Whilst the early case-studies of nebulised frusemide
suggested its use may be beneficial for breathlessness atl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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controlled trials failed to show benefit in people with
breathlessness as a result of advanced cancer [10,11]. Des-
pite these trials, the use of nebulised frusemide continues
to be reported in the literature [12,13].
Aim
The aim of this study was twofold. Firstly, to assess the
reported practice of off-label use of nebulised frusemide
for breathlessness by Australian physicians working in
palliative care in the previous 12 months and secondly,
to determine the feasibility and acceptability of using on-
line surveys for assessing practice usage and gathering
case reports.
Methods
The survey instrument (Additional file 1) was an investiga-
tor developed brief questionnaire that sought to assess the
prescribing of nebulised frusemide by Australian palliative
care physicians. An introduction letter explaining the pur-
pose of the survey and the link to survey was emailed to
249 Australian members of the Australian and New
Zealand Society of Palliative Medicine (ANZSPM). The
survey was conducted using the SurveyMonkey platform
(www.surveymonkey.com) and remained open for six
weeks.
The survey ascertained the basic demographics related to
medical specialty, highest palliative care qualification and
length of time working in palliative care. Respondents were
then asked if they had prescribed nebulised frusemide in
the previous 12 months. For those who had prescribed
nebulised frusemide, they were asked a series of questions
relating to their opinion of efficacy and prescribing practice
of nebulised frusemide. To establish in more detail the use
and perceived efficacy of nebulised frusemide, those who
had prescribed nebulised frusemide were given the option
to describe (basic demographics, diagnosis, co- morbidities,
treatments previously used for breathlessness, and any
agents co-prescribed and the impression of the efficacy) for
two cases where they had prescribed nebulised frusemide. If
respondents had not prescribed nebulised frusemide in the
previous 12 months, they were asked the main reason why
they had not prescribed it. Ethics approval was received
from Curtin University (SON&M 12-2010). Data are
reported as number (percentage) unless otherwise specified.
Results
Over a six week period, 52 responses were received. The
majority of respondents (41/52; 79%) to the survey were
palliative care consultants with 38/52 (73%) having dual
Fellowships to the Royal Australasian College of Physicians
and/or the Chapter of Palliative Medicine. The seniority of
the clinicians who answered the survey was also reflected
in the median length of time the respondents had beenworking in palliative care (14 years; interquartile range
[IQR] 6 to 17). Responses were received from all six states
in Australia with the majority of responses (41/51; 80%)
coming from the three most populated states (New South
Wales, Victoria and Queensland). One respondent did not
answer this item.
Physician’s reported practice related to nebulised
frusemide
The majority of respondents (44/52; 85%) had not used
nebulised frusemide in the previous 12 months. The
main reason cited for not using it were that they (18/44;
41%) believed there was not enough evidence to support
its use whilst only 6/44 (14%) were not convinced by its
efficacy. Figure 1 provides the full results for this item.
One respondent replied that they had not used nebulised
frusemide in the previous 12 months because they were
on maternity leave.
Only a small percentage of respondents (8/52; 15%)
reported using nebulised frusemide in the previous
12 months. Based on their experience of nebulised fru-
semide, the majority (6/8; 75%) indicated that there was
at least some use for nebulised frusemide. When asked
where in the treatment hierarchy nebulised frusemide
should be used, the majority (6/8; 75%) said that it
should be used as a fourth line treatment.
When asked about the frequency of dosing that the
respondents had prescribed nebulised frusemide, most
had prescribed it as either three times daily (2/8; 25%) or
four times daily (3/8; 38%). Two respondents (2/8; 25%)
responded that they had only prescribed nebulised fru-
semide as a PRN medication. Two respondents (2/3;
67%) who had prescribed nebulised frusemide as a four
times daily prescription had also prescribed nebulised
frusemide as a PRN medication. A PRN prescription was
also reported by a respondent (1/2; 50%) who had pre-
scribed nebulised frusemide as a three times daily pre-
scription. All respondents (8/8; 100%) reported that they
had prescribed 20 mg of nebulised frusemide.
Case series
The cases of prescribed nebulised frusemide in the previous
12 months by the respondents are presented in Table 1.
Half of the cases reported were patients with a primary
diagnosis of cancer (5/10; 50%) with the remaining having
either chronic cardiac disease or chronic respiratory dis-
ease. Two cases (20%) reported a primary diagnosis as both
chronic obstructive pulmonary disease and lung cancer.
Pleural effusion and heart failure were the most common
(3/10; 30%) problems causing breathlessness.
A number of therapies were reported as having been
used prior to nebulised frusemide with all (10/10; 100%)
having previously used oxygen and opioids. The majority
had also been previously prescribed steroids (8/10; 80%)
Figure 1 Reasons for not using nebulised frusemide in the previous 12 months (n = 43).
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were co-prescribed with nebulised frusemide: oxygen (8/
10; 80%), opioids (8/10; 80%), steroids (6/10; 60%), ben-
zodiazepines (7/10; 70%) and bronchodilators (5/10;
50%).
Most respondents reported that there was at least a
possible improvement (5/10; 50%) with 4/10 (40%) of
respondents reporting that there was an obvious im-
provement associated with the administration of nebu-
lised frusemide. One respondent (10%) was unsure if
there was any improvement associated with the use of
nebulised frusemide.
Survey acceptability
All respondents were asked to rate the level of difficulty
completing the survey on a five point scale (not difficult
at all – very difficult). The majority of respondents (47/
51; 91%) selected that the survey was not difficult to
complete whilst the remaining 4 (8%) respondents
selected that it was a bit difficult to complete. One re-
spondent (1/52; 2%) did not answer this item.
Respondents rated the usefulness of using an online sur-
vey to identify the prescribing patterns on a five point scale
(not useful at all – very useful). All respondents reported
that an online survey is at least somewhat useful with the
majority saying this method is useful (33/51; 65%) or very
useful (12/51; 24%). One (1/52; 2%) respondent did not
complete this item.
When asked would they be willing to participate in a
similar survey in the future, almost all respondents (47/50;
94%) said that they would be at least likely to participate
again. Only one respondent (1/52; 2%) said they would be
unlikely to participate in a similar survey again. Two (4%)
respondents did not complete this item.Discussion
The majority of respondents did not use nebulised frusem-
ide in the previous 12 months with the most common rea-
son being that they (18/44, 41%) did not believe there is
enough evidence to support its use. Whilst the early case
series [5-7] reported indicated nebulised frusemide may be
a useful novel therapy for breathlessness in advanced dis-
ease, two subsequent randomized trials have failed to show
the benefit of nebulised frusemide over placebo in people
with advanced cancer who remained breathless despite
treatment with more established therapies [10,11]. Of
those who had not used nebulised frusemide 7/44 (16%)
had used it at some point previously but either had not
been convinced of its efficacy (6/44; 14%) or the clinical
scenario had not arisen where they would prescribe it (1/
44; 2%). It is not known how long ago these respondents
had prescribed nebulised frusemide.
All respondents who reported prescribing nebulised fru-
semide in the previous 12 months (8/52, 15%) reported that
they had used 20 mg of frusemide. One respondent stated
that following a loading dose and “if the patient is very wet
and able to cope” they would use 40 mg. This is in keeping
with the reported case series [5-7] and clinical trials [10,11].
The failure of the clinical trials to show the benefit of bene-
fit of nebulised frusemide over placebo has seen some to
conclude that the benefit reported in the initial case series
was the result of a placebo effect [10].
Although there is limited evidence at best for the use of
nebulised frusemide for breathlessness due to advanced
disease, it is still being used by physicians even if only in
limited circumstances [12,13]. Like much of the breath-
lessness literature, both clinical trials and many of the
case-series were conducted in people with malignant dis-
ease. However, this survey has shown that some physicians
Table 1 Details of cases recalled by physicians where nebulised frusemide was used
Age Sex Primary diagnosis Main problem causing
breathlessness
Previous therapies for
breathlessness
Impression of clinical
efficacy
Comments
Case 1 70 Female NSCL cancer with COPD Bronchial obstruction Oxygen, Opioids, Steroids,
Benzodiazepines, Bronchodilators,
Antibiotics
Possible improvement No comments provided
Case 2 78 Male Pulmonary oedema Cardiac failure Oxygen, Opioids, Benzodiazepines Unsure of any benefit No comments provided
Case 3 60 Female CRC, lung metastases,
pleural effusion,
lymphangitis
Pleural effusion, lymphangitis Oxygen, Opioids, Steroids,
Benzodiazepines, Bronchodilators,
Drainage of pleural effusion
Possible improvement No comments provided
Case 4 84 Male Respiratory failure,
History of AF &
cardiomyopathy
Pulmonary fibrosis and
some mild LVF
Oxygen, Opioids, Nebulised
atrovent, Low dose midazolam
Obvious improvement No comments provided
Case 5 70’s Male COPD, Lung cancer COPD, Lung metastases Oxygen, Opioids, Steroids,
Benzodiazepines, Bronchodilators,
Antibiotics
Possible improvement No comments provided
Case 6 65 Male Not reported Not reported Oxygen, Opioids, Steroids,
Benzodiazepines
Possible improvement
frusemide
No comments provided
Case 7 60’s Female Stage IV NSCLC Cardiac failure Oxygen, Opioids, Steroids,
Benzodiazepines, Bronchodilators,
Antibiotics
Possible improvement No comments provided
Case 8 37 Female Lung cancer Local disease, airway
compromise, effusion
Oxygen, Opioids, Steroids,
Bronchodilators
Obvious improvement She was quite anxious and
benzo’s used helped
significantly but further
improvement seen after
adding lasix as well
Case 9 72 Female Metastatic vulval
cancer
Pleural effusion Oxygen, Opioids,
Steroids, Glycopyrolate
Obvious improvement Within 20 minutes, patient
came out of unconsciousness.
I am considering using now as
first line with atrovent when acute
episode occurs after chronic control.
Case 10 70’s Male Respiratory failure End stage COPD Oxygen, Opioids, Steroids,
Benzodiazepines, Bronchodilators,
Antibiotics
Obvious improvement Addition of nebulised frusemide
improved difficult dyspnea,
where all other modalities
had been tried;
NSCL Non-small cell carcinoma of the lung; COPD Chronic obstructive pulmonary disease; CRC colorectal cancer; AF atrial fibrillation; IHD: Ischemic heart disease.
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ditions. It was clear based on the responses that its use
was reserved once a number of other therapies, particu-
larly opioids and oxygen had been tried but had failed to
provide sufficient symptomatic relief. These data also
underscore the common and sometimes refractory burden
of breathlessness [14].
Limitations
Our response rate 52/249 (21%) is comparable to other
reported online physician surveys, [15] although some
have reported much higher [16] and lower [17] re-
sponse rates. Whilst traditional mail, fax or telephone
surveys report higher response rates than online sur-
veys, [15,16,18] we felt that the cost and time associated
with these modes of delivery prohibited their use in this
survey. It is likely that the response rate would have
been improved had we been able to send a reminder to
the respondents about the survey [19]. The use of
ANZSPM to distribute the invitation and the link to the
survey to its members limited the risk that the survey
was answered by a respondent who was either not a
physician (as ANZPM membership is only available to
physicians) and involved in the palliative care of
patients. Some authors have also suggested that
younger physicians are more likely to complete online
surveys than older physicians [15] however the majority
(41/52; 79%) of respondents in this survey were senior
physicians with a median of 14 (IQR 6 to 17) years
working in palliative care. It may be that the generation
of physicians that were more likely to respond to the
web-based surveys in these early reports are now the
senior clinicians willing to participate in online surveys.
Because of the mode of delivery of the survey, respon-
dents were limited to ANZSPM members with an email
address.
The cases reported in Table 1 relied on the clinician’s re-
call of the details and so there is the potential for recall bias.
This potential was one of the reasons why we only asked
respondents to report the use of nebulised frusemide in the
previous 12 months. Respondents who completed the case
details were asked if they would be willing to validate their
responses by reviewing the notes of the reported cases and
re-enter the information which would have allowed us to as-
sess recall bias. Unfortunately, only 3/8 (38%) respondents
who reported the use of nebulised frusemide said they would
be willing to do this. One respondent (33%) who was willing
to review the notes said they had subsequently moved inter-
state and no longer had access to the case notes. The
remaining two respondents did not log back into the survey
to enter the details. We were unable to send reminders to
these clinicians to re-enter the information after reviewing
the case notes. Future studies should try to capture this
information.Future research
As palliative care matures as a medical specialty, online
surveys provide a relative quick and easy opportunity to
better understand the prescribing practices of its pro-
fessionals. The majority of respondents in this survey
found it easy to use and indicated they would be willing
to participate in similar surveys in future. Online sur-
veys can and have been used to quickly gauge the opi-
nions of a range of physicians on a topic [20] which has
then directly contributed to the design and implemen-
tation of clinical research [21]. Given the limited, al-
though ever expanding evidence for treatments used in
palliative care, online surveys are a valuable method to
determine the research priorities for the specialty. Un-
deniably the state of equipoise for many in the use of
nebulised frusemide demands well designed clinical
trials in target populations using reliable and valid mea-
sures of outcome.
Conclusion
This online survey shows that despite only anecdotal
evidence of benefit and two small, negative randomized
controlled trials, nebulised frusemide continues to be
used by some Australian physicians working in pallia-
tive care. The continued use of nebulised frusemide in
people with intractable breathlessness despite optimal
treatment likely reflects the limited therapeutic options
available. Research must continue to determine if neb-
ulised frusemide is effective and in which clinical
situations.
Additional file
Additional file 1: The use of nebulised frusemide in Australian
palliative care survey.
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